Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...
Cancer a life-threatening disease can spread or metastasise from its original location to other parts of the body The lungs ...
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...
News Medical on MSN2d
Globally prostate and testicular cancer rates climb, but mortality is fallingNew research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...
Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases. The FDA has approved FoundationOne CDx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback